RET and lung cancer: The principal RET fusion partners in non–small-cell lung cancer (NSCLC) are kinesin family member 5B (KIF5B) (70–90%) and CCDC6 (10–25%), followed by NCOA4-RET, TRIM33-RET, ZNF477P-RET, ERCC1-RET, HTR4-RET, CLIP1-RET fusions (18%) (Table 1) [19].